Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_assertion type Assertion NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_head.
- NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_assertion description "[As current treatment for ATC is only palliative, and MV-NIS is currently Food and Drug Administration approved for human clinical trials in myeloma, our data indicate that targeting ATC with MV-NIS could prove to be a novel therapeutic strategy for effective treatment of iodine-resistant ATC and will expedite its testing in clinical trials for this aggressive disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_provenance.
- NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_assertion evidence source_evidence_literature NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_provenance.
- NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_assertion SIO_000772 22790962 NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_provenance.
- NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_assertion wasDerivedFrom befree-20140225 NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_provenance.
- NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_assertion wasGeneratedBy ECO_0000203 NP434655.RAhimcB1h4079NwYi_fRIhtao4ym4wIMWTJC0605u5llM130_provenance.